Zetagen closes an $12.908M Series B1 oversubscribed round

Zetagen Therapeutics has closed a $12.908M financing as part of its Series B1, a round that was decisively oversubscribed and reflects strong investor confidence in the company’s intratumoral approach to breast cancer. The funding circle drew notable appetite from private investors, underscoring a growing willingness to back platform-enabled oncology programs at clinical stage.

JSTAR Capital Investments, whose participation signals continued support for targeted, tumor-directed therapies that aim to minimize systemic toxicity. The capital will accelerate the advancement of Zetagen’s Zeta Platform, a delivery system designed to administer therapies directly into tumors, with the aim of improving therapeutic index across metastatic and primary breast cancer settings.

ZetaMet (Zeta-BC-003) for metastatic breast cancer to bone, ZetaMast (Zeta-MBC-005) for liver metastases, and ZetaPrime (Zeta-PBC-007) for HR+ breast cancer. Each candidate leverages the intratumoral delivery paradigm to constrain exposure to healthy tissue, a strategy increasingly viewed by investors as a route to de-risk early-stage oncology programs while potentially accelerating time to readouts.